Tranzyme Takes On Diabetic Gastroparesis With Novel Ghrelin Agonist
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Phase II efficacy data in hand for the I.V. version of its ghrelin agonist, Tranzyme Pharma has launched a Phase II safety and efficacy study of an oral outpatient formulation in patients with diabetic gastroparesis